Hepion Pharmaceuticals Inc (HEPA) News

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

EDISON, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage...

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Form 8-K - Current report

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B

Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B’s Late-Clinical Stage Candidate to...

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger

KIRYAT ONO, ISRAEL and EDISON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a...

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger

KIRYAT ONO, ISRAEL and EDISON, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pharma Two B Ltd. (“Pharma Two B”), a...

Form 425 - Prospectuses and communications, business combinations

Form 8-K - Current report

Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement

Pharma Two B Ltd. (“Pharma Two B”) has entered into a merger agreement with Hepion Pharmaceuticals, Inc...